摘要
目的观察白三烯受体拮抗剂孟鲁司特治疗成年人急性哮喘的疗效。方法选取急性哮喘患者85例,随机分为观察组和对照组。观察组43例给予口服孟鲁司特治疗,对照组42例给予强的松治疗。观察两组患者的哮喘控制水平、最大呼气峰流速(PEF)和肺功能指标(FEV1%)。结果治疗后,两组都取得了不错的控制效果(P<0.05),观察组的控制率达76.74%,显著高于对照组的66.67%(P<0.05);症状评分、PEF及肺功能方面比较,两组患者都较治疗前有显著改善(P<0.05),治疗后的昼间各指标比较两组差异不明显(P>0.05),夜间的各指标比较观察组显著优于对照组(P<0.05)。结论口服孟鲁司特治疗成年人急性哮喘疗效较好,可在临床推广。
Objective To observe the effect of leukotriene receptor antagonist montelukast in treating adult acute asthma. Methods 85 patients with acute asthma in our hospital were randomly divided into the observation group and the control group. 43 cases in the ob-servation group were given oral montelukast treatment, while 42 cases in the control group were given prednisone. The levels of asthma control, peak expiratory flow ( PEF ) and lung function index ( FEV1% ) were observed and compared between the two groups. Results Compared with before treatment, both groups achieved good control effect ( P﹤0. 05 ) , the control rate in the observation group reached 76. 74%, which was significantly higher than 66. 67% in the control group ( P﹤0. 05 );in the symptom score, PEF and lung function, the two groups were significantly improved after treatment compared before treatment ( P﹤0. 05 ) , the various indexes in daytime after treat-ment had no statistically significant difference between the two groups ( P﹥0. 05 ) , but which in nighttime in the observation group were significantly better than those in the control group ( P﹤0. 05 ) . Conclusion Oral montelukast has better effect for treating acute asthma in adults, which can be widely used in clinical practice.
出处
《中国药业》
CAS
2014年第13期68-70,共3页
China Pharmaceuticals